News | May 25, 2021
Nanoform and Celanese explore ways to enhance drug delivery
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Subscribe To Our Newsletter & Stay Updated
